Subscribe to Newsletter
Inside the Lab Oncology, Precision medicine, Genetics and epigenetics, Biochemistry and molecular biology, Technology and innovation, Training and education

NTRK fusion testing in lung cancer – another reason to implement broad molecular profiling

sponsored by Thermo Fisher Scientific

Now available on demand

With the emergence of a new class of targeted precision oncology therapies, NTRK fusions are increasingly becoming biomarkers that pathology laboratories can test for in FFPE tumor tissue. Although there are different testing options available such as IHC or FISH, NGS seems to be the preferred choice based on new guidelines. Register now to join us in discussing the pros and cons of different methods with the bigger picture in mind – the progress of precision oncology.

Learning Objectives of Webinar

  1. Why NTRK fusion testing is becoming important.
  2. What the different methods are including their pros and cons based on real data from lung cancer testing.
  3. How developments in precision oncology are changing not only cancer care, but also the way we should approach biomarker testing in our laboratories.

Now available on demand

Visit our Webinar Hub

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Application Notes
Tumor Genomic Profiling with SureSelect Cancer Tumor-Specific Assays

| Contributed by Agilent

Comprehensive Genomic Profiling with SureSelect Cancer CGP Assay

| Contributed by Agilent

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine